{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:45Z","timestamp":1753891965889,"version":"3.41.2"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Systemic juvenile idiopathic arthritis (sJIA), a particularly aggressive form of childhood arthritis, is characterized by persistent systemic inflammation. The most advanced treatments include biologic agents that target the interleukin-1(IL-1) and interleukin-6(IL-6) pathways. However, sJIA continue to pose challenging challenges for rheumatologists treating pediatric patients worldwide.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>1 children with sJIA was retrospectively collected from the Department of Rheumatology and immunology, Children's Hospital of Nanjing Medical University, Nanjing. Literature published between 2019 and 2024 was reviewed to understand the effect of tofacitinib on patients with sJIA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After a month of treatment of tofacitinib, there was a significant improvement in clinical symptoms and inflammatory indicators showed a marked decrease. As of July 2023, the patient's condition was effectively in remission. The efficacy of tofacitinib treatment was remarkable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Tofacitinib has shown good efficacy and safety in the treatment of sJIA patients, effectively controlling disease activity and relieving symptoms. The application of Janus kinase (JAK) inhibitors may offer a new treatment option for this disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1482762","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T07:08:40Z","timestamp":1739430520000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Tofacitinib treatment of systemic juvenile idiopathic arthritis: a case report and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Meifang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhidan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiguo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4274\/balkanmedj.2017.0111","article-title":"Juvenile idiopathic arthritis","volume":"34","author":"Barut","year":"2017","journal-title":"Balkan Med J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41584-023-01042-z","article-title":"Treatment of systemic juvenile idiopathic arthritis","volume":"19","author":"Hinze","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1080\/07853890.2022.2095431","article-title":"Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives","volume":"54","author":"Ambler","year":"2022","journal-title":"Ann Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/14740338.2021.1843631","article-title":"Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis\u2014data from the German BIKER registry","volume":"20","author":"Atemnkeng Ntam","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: a review in rheumatoid arthritis","volume":"77","author":"Dhillon","year":"2017","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-021-00332-8","article-title":"Juvenile idiopathic arthritis","volume":"8","author":"Martini","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1111\/1756-185X.13649","article-title":"Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: a single-center experience","volume":"22","author":"Barut","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"106480","DOI":"10.1016\/j.intimp.2020.106480","article-title":"The off-label uses profile of tofacitinib in systemic rheumatic diseases","volume":"83","author":"Zhao","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","article-title":"JAK inhibitors for rheumatoid arthritis","volume":"32","author":"Kubo","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.7499\/j.issn.1008-8830.2201081","article-title":"Recent research on tofacitinib in the treatment of pediatric rheumatic diseases","volume":"24","author":"Zhou","year":"2022","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e20182845","DOI":"10.1542\/peds.2018-2845","article-title":"Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis","volume":"143","author":"Huang","year":"2019","journal-title":"Pediatrics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40744-022-00496-z","article-title":"Sequential tocilizumab and tofacitinib treatment for systemic juvenile idiopathic arthritis: a case report","volume":"10","author":"Zhang","year":"2023","journal-title":"Rheumatol Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1136\/ard-2023-225094","article-title":"Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study","volume":"83","author":"Brunner","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1134312","DOI":"10.3389\/fped.2023.1134312","article-title":"JAK inhibitors in systemic juvenile idiopathic arthritis","volume":"11","author":"He","year":"2023","journal-title":"Front Pediatr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/rheumatology\/keac440","article-title":"JAK inhibitors in difficult-to-treat adult-onset still\u2019s disease and systemic-onset juvenile idiopathic arthritis","volume":"62","author":"Gillard","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update [published correction appears in Ann Rheum Dis. 2023 Mar;82(3):e76. doi: 10.1136\/ard-2022-223356corr1]","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1482762\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T07:08:43Z","timestamp":1739430523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1482762\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":17,"alternative-id":["10.3389\/fped.2025.1482762"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1482762","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"article-number":"1482762"}}